ERBA Diagnostics, Inc. Exhibits at Arab Health 2014, Dubai, U.A.E.

Worldwide Launch of New 6 plate automated Micrpoplate and IFA analyzer

Business Wire


ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, is pleased to announce that it will be exhibiting its full range of products at the largest Medical show in the Middle East and Africa, Arab Health in Dubai, U.A.E. Jan 27-30, 2014. ERBA, along with some of the world leaders in IVD, has been nominated as the GOLD Sponsor of the show.

This major show follows soon after the recent great success ERBA’s new products received at the world’s largest medical congress, MEDICA, in Germany end of November. Well known distributors from over 30 countries where ERBA is currently not represented have applied for being appointed as distributors.

For last 3 years, ERBA has been strongly focused on developing internal R&D capabilities for new products development. We are proud to launch 3 exciting new products developed by our Engineers in-house.

The Lisa XL is a fully automated, 6 plate analyzer and IFA processor targeted towards the larger Blood Banks, Infectious diseases and autoimmune market segments. With dual probe processing system it will have a faster throughput than most micro plate processors available in the market today. Combined with options of tips or needle only it will also be more flexible and economical for use in laboratories.

The Laura XL is a fully automated Urinalysis and sedimentation processor with the capability to automate Urine strip reading as well as performing sedimentation cell analysis for abnormal samples. The estimated IVD Urinalysis market is approximately $600 Million USD per year. Iris International (recently acquired by Danaher ) is the market leader in this space.

ERBA will also be showcasing the new Hb-Vario, an automated HPLC system that is capable of measuring both HbA1c/ and A2 for the monitoring of diabetes. Diabetes continues to be one of the major challenges worldwide to the healthcare industry. The benefits of monitoring A1c values to better manage diabetes is well documented in numerous studies. The measurement control of A1c values is key to reducing co-morbidity complications within this population.

Glycated hemoglobin (HbA1c) testing is poised to emerge as a popular technology with outpatient clinics and other small hospital-based laboratories according to a Global Industry Analyst report. The same report also forecasts that the global market for Diabetes Diagnostics is estimated to reach US$26 billion by the year 2015. Bio-Rad and Tosoh are the market leaders in this segment. Diabetes testing is a focus area for growth for ERBA.

With the launching of these three exciting products, ERBA expects to further grow its existing global market position in these three rapidly growing segments.

About ERBA Diagnostics, Inc.

ERBA Diagnostics, Inc. (, headquartered in Miami, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, for autoimmune and infectious diseases, Chemistry, Hematology and Diabetes testing through its six subsidiaries: Diamedix Corporation (U.S.), Delta Biologicals S.r.L. (Europe) and ImmunoVision, Inc. (U.S.)., Jas Diagnostics, Drew Scientific and ERBA Mexico

ERBA Diagnostics, Inc.
Mohan Gopalkrishnan, 305-418-2300 Ext 319 or Cell: 305-989-0866
Vice President Operations


View Comments (0)